Title
Category
Credits
Event date
Cost
- Disease management
- 0.75 ACPE - Pharmacists
- 0.75 ACPE - Pharmacy Technicians
- 0.75 AMA - Physicians
- 0.75 ANCC - Nurses
- 0.75 APA - Psychologists
- 0.75 Attendance - General Attendance
- 0.75 CDR - Dietitians
- 0.75 ASWB - Social Workers
$0.00
Join us to explore the role of personalized medicine in the management of inflammatory bowel disease (IBD), including the genetic and environmental factors that contribute to this disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) framework of evidence- and consensus-based recommendations for IBD treatment strategies will be reviewed, and the significance of biomarkers in guiding individualized therapy will be highlighted, with a focus on emerging therapies such as JAK inhibitors and S1P receptor modulators.
- Disease management
- 0.75 ACPE - Pharmacists
- 0.75 ACPE - Pharmacy Technicians
- 0.75 AMA - Physicians
- 0.75 ANCC - Nurses
- 0.75 APA - Psychologists
- 0.75 Attendance - General Attendance
- 0.75 CDR - Dietitians
- 0.75 ASWB - Social Workers
$0.00
This session will provide participants with an in-depth understanding of the role of genetic testing in pediatric oncology, focusing on the use of germline and tumor genetic testing in diagnosing and treating pediatric cancers. It will explore the development and application of rare-disease specific drugs as models for targeted therapy and analyze the differences and similarities in cancer development between pediatric and adult patients, highlighting the implications for treatment strategies. Participants will also develop strategies for incorporating genetic testing and targeted therapies into routine clinical practice.
- Disease management
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CDR - Dietitians
- 1.00 ASWB - Social Workers
$0.00
This activity will delve into the genetic predispositions and environmental factors contributing to the formation of aortic aneurysms (AA) and how these insights are leading to personalized treatment strategies. It will focus on advancements in screening, diagnosis and treatment, including ongoing research into new therapies such as intravenous immune-modulating cells that can potentially reduce aneurysm size.
- Disease management
- Vision
- 1.00 Attendance - General Attendance
- 1.00 COPE - Optometrists
$0.00
This activity will examine the multiple parts of eye anatomy, the dysfunction of which may contribute to dry eye syndrome, including the tear film, ocular anterior surface and Meibomian gland, and identify complications that can result when dry eye is left untreated. Importantly, a thorough review of optimal treatment regimens will be provided, as well as updates on newer and emerging targeted treatments, with a focus on providing relief and preventing further damage to the eye.
- Disease management
- Vision
- 1.00 Attendance - General Attendance
- 1.00 COPE - Optometrists
$0.00
Activity descriptionThis course provides an in-depth exploration of Healthcare Effectiveness Data and Information Set (HEDIS) measures, with a specific focus on the significance of diabetic eye exams. Participants will gain a comprehensive understanding of HEDIS, its domains, and the critical role it plays in evaluating health care quality and effectiveness. Provided byThis activity is provided by Optum Health Education and UnitedHealthcare Vision.Commercial supportNo commercial support was received for this activity.
- Behavioral health
- Disease management
- Wellness
- 0.75 ACPE - Pharmacists
- 0.75 ACPE - Pharmacy Technicians
- 0.75 AMA - Physicians
- 0.75 ANCC - Nurses
- 0.75 APA - Psychologists
- 0.75 Attendance - General Attendance
- 0.75 CDR - Dietitians
- 0.75 ASWB - Social Workers
$0.00
This activity will outline racial and socioeconomic status disparities and provide examples of why they may exist among different populations, identify challenges associated with the diagnosis and management of obesity, including diagnostic accuracy, access to care, and impact on health care costs and quality of life and discuss potential interventions that can reduce obesity care inequities.
- Disease management
- Rare diseases
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of KLA and other lymphatic conditions, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s).
- Disease management
- Rare diseases
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 ASWB - Social Workers
$0.00
This activity will explore the recent advances in the diagnosis and treatment of achondroplasia and other causes of disproportionate short stature. It will also share the importance of the interprofessional team to provide insights, perspectives and strategies to support the well-being of both the individual and their family/caregiver(s).
- Disease management
- Rare diseases
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 APA - Psychologists
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of Pompe disease and other LSDs, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s) and highlight the role of the interprofessional team in evaluating and improving care for patients with these conditions.